

LABONE INC/
Form 10-Q
November 09, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For quarterly period ended September 30, 2004

Commission file number: 0-16946

LabOne, Inc.

10101 Renner Blvd.

Lenexa, Kansas 66219

(913) 888-1770

Incorporated in Missouri

I.R.S. Employer Identification Number: 43-1039532

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes /X/ No / /

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes /X/ No / /

Number of shares outstanding of the only class of Registrant's common stock, \$.01 par value, as of October 29, 2004 - 17,173,433.

LabOne, Inc.

Form 10-Q for the Third Quarter, 2004

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements:

Consolidated Balance Sheets

Consolidated Statements of Operations

Consolidated Statement of Stockholders' Equity

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Selected Financial Data

Third Quarter Analysis

Year to Date Analysis

Financial Position, Liquidity and Capital Resources

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

ITEM 4. Controls and Procedures

PART II. OTHER INFORMATION

SIGNATURES

PART I. FINANCIAL INFORMATION

ITEM 1 - Financial Statements

LabOne, Inc. and Subsidiaries

Consolidated Balance Sheets
(in thousands, except share and per share data)

September 30, December 31,

| | 2004 <u>(unaudited)</u> | 2003 <hr/> |
|--|----------------------------|-------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 20,592 | \$ 4,651 |
| Accounts receivable, net of allowance for doubtful accounts of \$4,329 in 2004 and \$6,123 in 2003 | 73,429 | 57,928 |
| Inventories | 6,397 | 5,472 |
| Prepaid expenses and other current assets | 6,590 | 5,202 |
| Deferred income taxes | <u>5,833</u> | <u>4,990</u> |
| Total current assets | 112,841 | 78,243 |
| Property, plant and equipment, net | 58,232 | 47,405 |
| Goodwill | 137,699 | 99,103 |
| Intangible assets, net | 21,694 | 11,345 |
| Other long-term assets | <u>4,936</u> | <u>1,526</u> |
| Total assets | \$ <u>335,402</u> | \$ <u>237,622</u> |
| Liabilities and Stockholders' Equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 23,355 | \$ 13,617 |
| Accrued payroll and benefits | 17,193 | 11,769 |
| Other accrued expenses | 4,771 | 2,787 |
| Current portion of long-term debt | <u>1,955</u> | <u>2,014</u> |
| Total current liabilities | 47,274 | 30,187 |
| Deferred income taxes | 6,683 | 5,619 |
| Long-term debt | 111,448 | 56,094 |
| Other | <u>34</u> | <u>21</u> |
| Total liabilities | 165,439 | 91,921 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Common stock, \$0.01 par value per share. Authorized 40,000,000 shares; issued 18,027,729 shares in 2004 and 2003 | 180 | 180 |
| Additional paid-in capital | 86,361 | 84,066 |
| Retained earnings | 95,031 | 76,250 |
| Accumulated other comprehensive loss | (247) | (245) |
| Treasury stock of 894,071 shares in 2004 and 1,144,840 shares in 2003, at cost | <u>(11,362)</u> | <u>(14,550)</u> |
| Total stockholders' equity | <u>169,963</u> | <u>145,701</u> |

Total liabilities and stockholders' equity **\$ 335,402** **\$ 237,622**

See accompanying notes to consolidated financial statements.

LabOne, Inc. and Subsidiaries

Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)

See accompanying notes to consolidated financial statements.

LabOne, Inc. and Subsidiaries

Consolidated Statement of Stockholders' Equity
Nine Months Ended September 30, 2004
(in thousands, except share data)
(unaudited)

| | Common stock | Additional paid-in capital | Retained earnings | Accumulated other comprehensive loss | Treasury stock | Comprehensive income | Total stockholders' equity |
|---|-------------------------|---|------------------------------|---|---------------------------|---------------------------------|---|
| Balance at December 31, 2003 | \$ 180 | \$ 84,066 | \$ 76,250 | \$ (245) | \$ (14,550) | | \$ 145,701 |
| Comprehensive income: | | | | | | | |
| Net earnings | | | 18,781 | | | \$ 18,781 | 18,781 |
| Adjustment from foreign currency translation | | | | (2) | | <u>(2)</u> | (2) |
| Comprehensive income | | | | | | <u>\$ 18,779</u> | |
| Stock options exercised (249,111 shares) | | 708 | | | 3,167 | | 3,875 |
| Tax benefit from exercise of stock options | | 1,558 | | | | | 1,558 |
| Directors' stock compensation (1,658 shares) | | <u>29</u> | | | <u>21</u> | | <u>50</u> |
| Balance as of September 30, 2004 | <u>\$ 180</u> | <u>\$ 86,361</u> | <u>\$ 95,031</u> | <u>\$ (247)</u> | <u>\$ (11,362)</u> | | <u>\$ 169,963</u> |

See accompanying notes to consolidated financial statements.

LabOne, Inc. and Subsidiaries

Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

| | Nine months ended September 30, | |
|---|--|-----------------------|
| | <u>2004</u> | <u>2003</u> |
| Cash flows from operating activities: | | |
| Net earnings | \$ 18,781 | \$ 14,983 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | | |
| Depreciation and amortization | 13,396 | 8,512 |
| Provision for loss on accounts receivable | 6,833 | 5,074 |
| Income tax benefit from exercise of stock options | 1,558 | 646 |
| Deferred income taxes | 220 | (1,681) |
| Directors' stock compensation | 50 | 17 |
| (Gain) loss on sale of property, plant and equipment | 63 | (12) |
| Change in assets and liabilities, net of effects of acquisitions: | | |
| Accounts and note receivable | (19,068) | (13,018) |
| Inventories | 464 | (400) |
| Prepaid expenses and other current assets | (1,240) | (966) |
| Accounts payable | 9,178 | 2,065 |
| Accrued payroll and benefits | 5,425 | 3,104 |
| Other accrued expenses | 1,762 | 971 |
| Other | <u>(131)</u> | <u>(142)</u> |
| Net cash provided by operations | 37,291 | 19,153 |
| Cash flows from investing activities: | | |
| Capital expenditures | (16,162) | (5,944) |
| Acquisition of businesses | (60,110) | (7,202) |
| Proceeds from sale of property, plant, and equipment | 36 | 55 |
| Acquisition of patents and trademarks | <u>(40)</u> | <u> </u> |
| Net cash used in investing activities | (76,276) | (13,091) |
| Cash flows from financing activities: | | |
| Net payments on line of credit | (46,253) | (5,000) |
| Net proceeds from issuance of convertible debentures | 100,144 | |
| Debt issue costs | (845) | |
| Payments on other long-term debt | (2,011) | (1,920) |
| Proceeds from exercise of stock options | 3,875 | 3,685 |
| Purchase of treasury stock | <u> </u> | <u>(1,556)</u> |
| Net cash provided by (used in) financing activities | 54,910 | (4,791) |
| Effect of foreign currency translation on cash | <u>16</u> | <u>294</u> |
| Net increase in cash and cash equivalents | 15,941 | 1,565 |
| Cash and cash equivalents at beginning of period | <u>4,651</u> | <u>8,108</u> |

Edgar Filing: LABONE INC/ - Form 10-Q

| | | |
|---|------------------|-----------------|
| Cash and cash equivalents at end of period | <u>\$ 20,592</u> | <u>\$ 9,673</u> |
| Supplemental disclosures of cash flow information: | | |
| Cash paid during the period for: | | |
| Income taxes | \$ 8,955 | \$ 9,797 |
| Interest | 2,195 | 1,630 |
| Supplemental schedule of non-cash investing and financing activities: | | |
| Preferred stock dividends payable in kind | \$ | \$ 2,349 |
| Details of acquisitions: | | |
| Fair value of assets acquired | \$ 60,928 | \$ 8,413 |
| Liabilities assumed | <u>(818)</u> | <u>(1,211)</u> |
| Cash paid for acquisitions | <u>\$ 60,110</u> | <u>\$ 7,202</u> |
| See accompanying notes to consolidated financial statements. | | |

LabOne, Inc. and Subsidiaries

Notes to Consolidated Financial Statements
(Unaudited)

(1) Basis of Presentation

Description of Business

LabOne, Inc. ("LabOne" or the "Company") is a diagnostic services provider. The services and information LabOne and its subsidiaries provide include: risk assessment information services for the insurance industry; diagnostic healthcare testing; and substance abuse testing services and related employee qualification products.

The financial information furnished herein as of September 30, 2004, and for the periods ended September 30, 2004 and 2003, is unaudited; however, in the opinion of management, it reflects all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state the Company's financial position, the results of its operations and its cash flows. The balance sheet information as of December 31, 2003 has been derived from the audited consolidated financial statements as of that date. The financial statements have been prepared in conformity with generally accepted accounting principles in the United States appropriate in the circumstances, and included in the financial statements are certain amounts based on management's estimates and judgments.

The financial information herein is not necessarily representative of a full year's operations because levels of sales, capital additions and other factors fluctuate throughout the year. These same considerations apply to all year-to-year comparisons. Certain information and note disclosures normally included in the Company's annual financial statements have been condensed or omitted. These condensed, consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2003.

Certain amounts have been reclassified from the prior period consolidated financial statements to conform with the current year presentation.

(2) Acquisitions

The following table summarizes the estimated fair value of the assets acquired and liabilities assumed for businesses acquired during the first nine months of 2004:

| | Laboratory Operations of <u>The Health Alliance</u> | Northwest <u>Toxicology</u> | Paramedical Service <u>Providers</u> |
|---|--|--|---|
| | (in thousands) | | |
| Current assets | \$ 1,614 | \$ 2,718 | \$ 771 |
| Property, plant and equipment | 2,932 | 812 | 215 |
| Goodwill | 29,490 | 7,506 | 1,521 |
| Intangible assets: | | | |
| Non compete and non solicitation agreements | 1,200 | 300 | 76 |
| Customer contract | 3,500 | | |
| Customer relations | 5,200 | 950 | 1,957 |
| Other long-term assets | <u> </u> | <u> 11</u> | <u> 5</u> |
| Total assets acquired | 43,936 | 12,297 | 4,545 |
| Current liabilities | | 22 | 762 |
| Current portion of long-term debt | <u> </u> | <u> 34</u> | <u> </u> |
| Total liabilities assumed | <u> </u> | <u> 56</u> | <u> 762</u> |
| Net assets acquired | <u>\$ 43,936</u> | <u>\$ 12,241</u> | <u>\$ 3,783</u> |

Laboratory Operations of The Health Alliance

On January 4, 2004, the Company acquired, for cash, substantially all of the assets associated with the core laboratory operations of The Health Alliance of Greater Cincinnati (the "Health Alliance") for \$43,936,000, including transaction and other costs of \$1,586,000. The core laboratory operations acquired provide outreach laboratory testing services for physicians in the Greater Cincinnati area and reference laboratory for the six hospitals affiliated with the Health Alliance. In connection with the acquisition, the Company entered into a long-term service agreement for the Company to provide reference testing for the Health Alliance hospitals and management of their six immediate response laboratories.

Goodwill of \$29,490,000, including workforce in place, was assigned to the clinical - health care services segment and is expected to be deductible for tax purposes. The amortization periods for the intangible assets acquired are: non compete and non solicitation agreement - 10 years; customer contract - 5 years; and customer relations - 10 years.

Northwest Toxicology

On March 1, 2004, the Company acquired, for cash, substantially all of the net assets of the drug testing division, Northwest Toxicology, from NWT Inc. for \$12,241,000, including net working capital of \$2,159,000 and transaction costs of \$82,000. The acquisition will result in additional urine

and oral fluid testing volumes directed to LabOne's Lenexa, Kansas laboratory, and furthers the Company's capabilities to include drugs of abuse testing in blood, expanded specimen validity testing, medical professional and other esoteric drug testing.

Goodwill of \$7,506,000, including workforce in place, was assigned to the clinical - substance abuse testing segment and is expected to be deductible for tax purposes. The amortization periods for the intangible assets acquired are: non compete and non solicitation agreement - 10 years and customer relations - 10 years.

Paramedical Service Providers

During the first nine months of 2004, the Company acquired, for cash, four paramedical service provider companies in the United States and one paramedical service provider company in Canada. The acquired businesses provide paramedical examinations that are used to assist life insurance companies in objectively evaluating the mortality and morbidity risks posed by policy applicants.

Goodwill of \$1,521,000 was assigned to the risk assessment services segment and is expected to be deductible for tax purposes. The weighted average amortization periods for the non compete and non solicitation agreements and customer relations are 10 years and 7.7 years, respectively.

All of the above acquisitions have been accounted for under the purchase method and, accordingly, the operating results of the acquired companies have been included in the consolidated statements of operations from the dates of acquisition. Certain of these acquisitions are subject to contingent payment agreements which will be recorded when earned. Supplemental pro forma information for these acquisitions is not included, as such business combinations are not material individually or in the aggregate.

(3) Long-term Debt

During June 2004, the Company issued \$90,000,000 of 3.50% convertible senior debentures due June 15, 2034 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. During July 2004, the initial purchasers exercised their option to purchase an additional \$13,500,000 of the debentures. The debentures may be converted, under certain circumstances, into a combination of cash and common stock of the Company at an initial rate equivalent to a conversion price of \$39.30 per share of common stock, subject to certain adjustments. Holders may convert the debentures if the common stock price exceeds 130% of the conversion price for 20 trading days in the 30 trading day period ending on the last trading day of the preceding fiscal quarter. Upon conversion, the Company will deliver cash equal to the lesser of the aggregate principal amount of debentures to be converted and the conversion obligation, and common stock in respect of the remainder, if any, of the conversion obligation. The Company may not redeem the debentures prior to June 20, 2009. Holders of the debentures may require the Company to repurchase some or all of the debentures on June 15, 2011, 2014 and 2024 and upon certain specified corporate transactions. The Company used the net proceeds from the offering to reduce borrowings under its credit facility and for general corporate purposes.

(4) Earnings Per Share

Basic earnings per share is computed using net earnings available to common shareholders divided by the weighted average number of common shares outstanding. Diluted earnings per share includes the effects of outstanding stock options and common shares issuable upon conversion of preferred stock, if dilutive. In addition, the related preferred stock dividends are added back to income since they would not be paid if the preferred stock were converted to common stock. There was no dilutive effect of conversion of the debentures as the market price of LabOne common stock was below the conversion price and the par value of the

debentures would be settled in cash. Subject to adjustment under certain circumstances as described in the terms of the convertible debentures, the conversion obligation is generally based upon the product of the conversion rate then in effect (25.4463 as of September 30, 2004) and the closing price of LabOne common stock over the measurement period. Should the debentures become convertible under the terms of the conversion rights with a stock price of \$51.09 over the measurement period, the conversion obligation would be approximately \$1,300 (25.4463 x \$51.09), and the settlement upon conversion would consist of \$1,000 cash and 5.87 shares (\$300/\$51.09) of common stock, per \$1,000 principal amount of debentures converted, assuming none of the adjustment provisions in the debenture applied to such calculation.

The following table reconciles the weighted average common shares used in the basic earnings per share calculation and the weighted average common shares and common share equivalents used in the diluted earnings per share calculation:

| | Three Months Ended September 30, 2004 | | Nine Months Ended September 30, 2004 | |
|--|--|----------------------|---|----------------------|
| | 2003 | 2004 | 2003 | 2004 |
| | (in thousands) | | | |
| Weighted average common shares for basic earnings per share | 11,908 | 17,113 | 11,757 | 17,039 |
| Dilutive effect of employee stock options | 310 | 364 | 264 | 420 |
| Dilutive effect of common shares issuable upon conversion of preferred stock | <u>4,757</u> | <u>—</u> | <u>4,775</u> | <u>—</u> |
| Weighted average common shares for dilutive earnings per share | <u>16,975</u> | <u>17,477</u> | <u>16,796</u> | <u>17,459</u> |

(5) Stock-based Compensation

The Company applies the intrinsic-value based method of accounting prescribed by Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, and related interpretations including FASB Interpretation No. 44, *Accounting for Certain Transactions Involving Stock Compensation, an interpretation of APB Opinion No. 25*, to account for its fixed-plan stock options. Under this method, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeds the exercise price. Statement of Financial Accounting Standards ("SFAS") No. 123, *Accounting for Stock-Based Compensation*, as amended by SFAS No. 148, *Accounting for Stock-Based Compensation - Transition and Disclosure, an amendment of FASB Statement No. 123*, established accounting and disclosure requirements using a fair-value based method of accounting for stock-based employee compensation plans. As allowed by SFAS No. 123, as amended by SFAS No. 148, the Company has elected to continue to apply the intrinsic-value based method of accounting described above and has adopted only the disclosure requirements of SFAS No. 123.

The following table illustrates the effect on net earnings if the fair-value based method had been applied to all outstanding and unvested options in each period.

| | Three Months Ended September 30, | Nine Months Ended September 30, |
|--|---|--|
|--|---|--|

Edgar Filing: LABONE INC/ - Form 10-Q

| | <u>2004</u> | <u>2003</u> | <u>2004</u> | <u>2003</u> |
|---|------------------------|-----------------|-------------------------|------------------|
| | (in thousands) | | | |
| Net earnings, as reported | \$ 6,615 | \$ 5,388 | \$ 18,781 | \$ 14,983 |
| Deduct total stock-based employee compensation expense determined under fair-value based method for all stock options, net of tax | <u>(528)</u> | <u>(324)</u> | <u>(1,302)</u> | <u>(1,132)</u> |
| Pro forma net earnings | <u>\$ 6,087</u> | <u>\$ 5,064</u> | <u>\$ 17,479</u> | <u>\$ 13,851</u> |
| Basic earnings per share: | | | | |
| As reported | \$ 0.39 | \$ 0.39 | \$ 1.10 | \$ 1.07 |
| Pro forma | \$ 0.36 | \$ 0.36 | \$ 1.03 | \$ 0.98 |
| Diluted earnings per share: | | | | |
| As reported | \$ 0.38 | \$ 0.32 | \$ 1.08 | \$ 0.89 |
| Pro forma | \$ 0.35 | \$ 0.30 | \$ 1.00 | \$ 0.82 |

(6) Business Segment Information

The Company operates principally in two lines of business: risk assessment services and clinical. Risk assessment services is segregated into insurance laboratory, paramedical services and other insurance services. Clinical is segregated into healthcare services and substance abuse testing.

Following is a summary of segment information:

| | Three Months Ended | | Nine Months Ended | |
|--------------------------------|---------------------------|------------------|--------------------------|-------------------|
| | September 30, | | September 30, | |
| | <u>2004</u> | <u>2003</u> | <u>2004</u> | <u>2003</u> |
| | (in thousands) | | | |
| Sales: | | | | |
| Risk assessment services: | | | | |
| Insurance laboratory | \$ 20,708 | \$ 21,175 | \$ 65,231 | \$ 66,649 |
| Paramedical services | 26,129 | 21,817 | 75,799 | 62,919 |
| Other insurance services | <u>17,809</u> | <u>14,991</u> | <u>53,171</u> | <u>39,506</u> |
| Total risk assessment services | 64,646 | 57,983 | 194,201 | 169,074 |
| Clinical: | | | | |
| Healthcare services | 42,241 | 22,847 | 124,275 | 64,692 |
| Substance abuse testing | <u>10,952</u> | <u>7,285</u> | <u>29,670</u> | <u>20,240</u> |
| Total clinical | <u>53,193</u> | <u>30,132</u> | <u>153,945</u> | <u>84,932</u> |
| Total | <u>\$ 117,839</u> | <u>\$ 88,115</u> | <u>\$ 348,146</u> | <u>\$ 254,006</u> |

Operating earnings:

Risk assessment services:

Edgar Filing: LABONE INC/ - Form 10-Q

| | | | | |
|--------------------------------|-----------------------|-----------------|-----------------------|------------------|
| Insurance laboratory | \$ 8,543 | \$ 9,582 | \$ 26,876 | \$ 29,724 |
| Paramedical services | 3,203 | 2,075 | 8,533 | 5,437 |
| Other insurance services | 2,475 | 1,247 | 7,900 | 3,658 |
| Risk assessment sales group | <u>(1,752)</u> | <u>(1,350)</u> | <u>(4,884)</u> | <u>(4,072)</u> |
| Total risk assessment services | 12,469 | 11,554 | 38,425 | 34,747 |
| Clinical: | | | | |
| Healthcare services | 7,591 | 4,973 | 19,888 | 12,362 |
| Substance abuse testing | <u>1,976</u> | <u>1,451</u> | <u>5,105</u> | <u>3,418</u> |
| Total clinical | 9,567 | 6,424 | 24,993 | 15,780 |
| General corporate expenses | (10,435) | (8,666) | (29,856) | (24,803) |
| Total other expenses, net | <u>(1,315)</u> | <u>(773)</u> | <u>(3,728)</u> | <u>(1,975)</u> |
| Earnings before income taxes | 10,286 | 8,539 | 29,834 | 23,749 |
| Provision for income taxes | <u>3,671</u> | <u>3,151</u> | <u>11,053</u> | <u>8,766</u> |
| Net earnings | \$ 6,615 | \$ 5,388 | \$ 18,781 | \$ 14,983 |

(7) Commitments and Contingencies

The Company is a party to various claims or lawsuits related to services performed in the ordinary course of the Company's activities. The Company's management and legal counsel anticipate potential claims resulting from such matters that would not be covered by insurance and have appropriately provided for these claims in the consolidated financial statements. The Company believes that the ultimate resolution of these matters will not materially affect the consolidated financial statements of the Company.

ITEM 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations.

LabOne is a diagnostic services provider. The services and information LabOne and its subsidiaries provide include: risk assessment information services for the insurance industry; diagnostic healthcare testing; and substance abuse testing services and related employee qualification products. LabOne's business plan is to be the premier provider of certified and accredited, cost effective laboratory and information services to life and health insurance companies, employers, third party administrators, government agencies, hospitals, physician practices and occupational health clinics.

LabOne's risk assessment services comprise underwriting support services to the insurance industry including teleunderwriting, specimen collection and paramedical examinations, laboratory testing, telephone inspections, motor vehicle reports and medical record retrieval. The laboratory tests performed and data gathered by the Company are specifically designed to assist an insurance company in objectively evaluating the mortality and morbidity risks posed by policy applicants. The majority of the testing is performed on specimens of individual life insurance policy applicants, but also includes specimens of individuals applying for individual and group medical and disability policies.

LabOne's clinical services include laboratory testing services for the healthcare industry as an aid in the diagnosis and treatment of patients. LabOne operates highly automated and centralized laboratory facilities, which the Company believes has significant economic advantages over other laboratory competitors. LabOne markets its clinical testing

services to managed care companies, insurance companies, self-insured groups, hospitals and physicians.

LabOne's clinical services also include substance abuse testing ("SAT") provided to employers to support their drug free workplace programs. LabOne is certified by the Substance Abuse and Mental Health Services Administration to perform substance abuse testing services for federally regulated employers and currently markets these services throughout the country to both regulated and nonregulated employers. Additionally, the Company can provide background checks, social security number verification and other pre-employment data required by employers. The Company's rapid turnaround times and multiple testing options help clients reduce downtime for affected employees and meet mandated drug screening guidelines.

Forward Looking Statements

This Quarterly Report on Form 10-Q may contain "forward-looking statements," including, but not limited to, statements of plans and objectives, statements of future economic performance and statements of assumptions underlying such statements, and statements of the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future. Forward-looking statements can often be identified by the use of forward-looking terminology, such as "could," "should," "will," "will be," "intended," "continue," "believe," "may," "hope," "anticipate," "goal," "forecast," "plan," "estimate" or variations thereof. Forward-looking statements are not guarantees of future performance or results. Forward-looking statements are based on estimates, forecasts and assumptions involving risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in such forward-looking statements. The uncertainties, risks and assumptions referred to above include, but are not limited to, those described under "Factors Affecting Future Performance" in Item 7 detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2003 and those described under "Risk Factors" in the Company's S-3 registration statement filed with the Securities and Exchange Commission on September 10, 2004. Investors are cautioned not to put undue reliance on any forward-looking statement.

RESULTS OF OPERATIONS

SELECTED FINANCIAL DATA

| | Three Months Ended September 30, | | | |
|--------------------------------|---|--------------------|------------------|-------------|
| | <u>2004</u> | | <u>2003</u> | |
| | (in thousands) | | | |
| <u>Revenues:</u> | | | | |
| Risk assessment services | | | | |
| Insurance laboratory | \$ 20,708 | 18% | \$ 21,175 | 24% |
| Paramedical services | 26,129 | 22% | 21,817 | 25% |
| Other insurance services | <u>17,809</u> | <u>15%</u> | <u>14,991</u> | <u>17%</u> |
| Total risk assessment services | 64,646 | 55% | 57,983 | 66% |
| Clinical | | | | |
| Healthcare services | 42,241 | 36% | 22,847 | 26% |
| Substance abuse testing | <u>10,952</u> | <u>9%</u> | <u>7,285</u> | <u>8%</u> |
| Total clinical | <u>53,193</u> | <u>45%</u> | <u>30,132</u> | <u>34%</u> |
| Total | <u>\$117,839</u> | <u>100%</u> | <u>\$ 88,115</u> | <u>100%</u> |

| | | |
|-----------------------------------|------------------|-----------|
| Total laboratory services revenue | \$ 73,901 | \$ 51,307 |
|-----------------------------------|------------------|-----------|

Volumes:

Risk assessment services

| | | |
|----------------------|--------------|-------|
| Insurance laboratory | 1,211 | 1,217 |
| Paramedical services | 330 | 280 |

Clinical

| | | |
|-------------------------|--------------|-----|
| Healthcare services | 1,163 | 648 |
| Substance abuse testing | 877 | 608 |

THIRD QUARTER ANALYSIS

Revenue for the quarter ended September 30, 2004, was \$117.8 million compared to \$88.1 million in the third quarter 2003. The increase of \$29.7 million, or 34%, was due to increases in clinical healthcare revenue of \$19.4 million, risk assessment revenue of \$6.7 million and clinical SAT revenue of \$3.7 million. Risk assessment revenue increased to \$64.6 million from \$58.0 million in the third quarter 2003 due primarily to increases of \$4.3 million in paramedical services and \$2.8 million in other insurance services, partially offset by a decrease in insurance laboratory services of \$0.5 million. Paramedical services revenue increased due to an increase in the number of paramedical exams performed from new customer accounts and the acquisition of a Canadian paramedical provider. Other insurance services increased primarily due to growth in teleunderwriting services, motor vehicle reports and medical records retrieval. Insurance laboratory revenue decreased due to a 3% decline in the average revenue per applicant. During the third quarter 2004, healthcare services revenue increased to \$42.2 million from \$22.8 million in 2003 due to the acquisition of Alliance Laboratory Services in January 2004 and a 19% increase in organic testing volumes. Alliance Laboratory Services accounted for \$14.1 million of the revenue increase, and increased sales to new and existing healthcare customers accounted for \$5.3 million of the revenue increase. SAT revenue increased \$3.7 million to \$11.0 million in the third quarter 2004 from \$7.3 million in 2003 due to the addition of Northwest Toxicology and an 11% increase in organic testing volumes. Northwest Toxicology accounted for \$3.0 million of this increase. Total laboratory services revenue from risk assessment and clinical was \$73.9 million as compared to \$51.3 million in the third quarter 2003.

Cost of sales increased \$20.7 million, or 34%, in the third quarter 2004 as compared to the prior year, due primarily to the acquisitions of Alliance Laboratory Services and Northwest Toxicology, and increases in paramedical collections, motor vehicle report fees and payroll expense. Paramedical services increased primarily due to continued growth of the ExamOne paramedical operations and the acquisition of a Canadian paramedical provider. Motor vehicle report fees increased due to sales growth. Payroll increased due to increased specimen volume in the healthcare and substance abuse laboratory testing segment and growth of teleunderwriting. Risk assessment cost of sales, including all of the above mentioned factors, increased to \$46.9 million in 2004 from \$41.9 million in the third quarter 2003. Clinical healthcare cost of sales increased to \$26.4 million as compared to \$13.2 million in the third quarter 2003 primarily due to the addition of Alliance Laboratory Services. Clinical SAT cost of sales expenses increased to \$7.5 million as compared to \$5.1 million in the third quarter 2003 primarily due to the addition of Northwest Toxicology.

As a result of the above factors, gross profit for the quarter increased \$9.0 million, or 32%, from \$28.0 million in 2003 to \$37.0 million in 2004. Risk assessment gross profit increased \$1.7 million, or 10%, to \$17.7 million in the third quarter 2004. Clinical healthcare gross profit increased \$6.2 million, or 64%, to \$15.8 million in 2004 from \$9.7 million in 2003. Clinical SAT gross profit increased \$1.2 million, or 55%, to \$3.4 million in 2004 from \$2.2 million in the third quarter last year.

Selling, general and administrative expenses increased \$6.8 million, or 36%, in the third quarter 2004 as compared to the prior year. This increase is primarily due to increases in payroll, amortization, depreciation and audit and bank fees. Risk assessment overhead expenditures increased to \$5.2 million in 2004 from \$4.5 million in the third quarter 2003. Clinical healthcare overhead expenditures increased to \$8.2 million as compared to \$4.7 million in 2003 due to the acquisition of Alliance Laboratory Services and an increase in payroll expense. Clinical healthcare expenses were reduced in the period by \$0.2 million related to a reimbursement from the Health Alliance for certain transition costs incurred by the Company in connection with the laboratory integration. Clinical SAT overhead expenditures increased to \$1.5 million as compared to \$0.8 million in 2003 due to the acquisition of Northwest Toxicology. Corporate overhead expenses increased to \$10.4 million from \$8.7 million in the third quarter 2003 primarily due to higher payroll and depreciation, principally related to information technology initiatives and expenses related to compliance with the Sarbanes-Oxley Act of 2002.

Operating earnings increased 25% from \$9.3 million in the third quarter 2003 to \$11.6 million in 2004. Risk assessment services operating earnings increased 8% to \$12.5 million in 2004 as compared to \$11.6 million in the third quarter 2003. Clinical healthcare services operating income increased 53% to \$7.6 million in 2004 as compared to \$5.0 million in 2003. Clinical SAT operating earnings increased 35% to \$2.0 million in the third quarter 2004 as compared to \$1.5 million in 2003. Corporate operating expenses increased 20% to \$10.4 million compared to \$8.7 million in the third quarter 2003.

Non operating expenses increased \$0.5 million primarily due to higher interest expense from increased borrowings for acquisitions. The effective income tax rate declined to 36% in the third quarter 2004 as compared to 37% in 2003. Income tax expense for the period was favorably impacted by a \$0.4 million adjustment related to foreign and state taxes.

The combined effect of the above factors resulted in net earnings of \$6.6 million, or \$0.38 per diluted share in the third quarter 2004, compared to \$5.4 million, or \$0.32 per diluted share in 2003. Convertible preferred dividends in the third quarter 2003 were \$0.8 million and earnings available to common shareholders were \$4.6 million. The preferred stock was converted into LabOne common stock during the third and fourth quarters of 2003.

| | Nine Months Ended | | | |
|-----------------------------------|--------------------------|-------------------|---------------|------------|
| | September 30, | | | |
| | <u>2004</u> | | <u>2003</u> | |
| | (in thousands) | | | |
| Revenues: | | | | |
| Risk assessment services | | | | |
| Insurance laboratory | \$ 65,231 | 19% | \$ 66,649 | 26% |
| Paramedical services | 75,799 | 22% | 62,919 | 25% |
| Other insurance services | <u>53,171</u> | <u>15%</u> | <u>39,506</u> | <u>16%</u> |
| Total risk assessment services | 194,201 | 56% | 169,074 | 67% |
| Clinical | | | | |
| Healthcare services | 124,275 | 36% | 64,692 | 25% |
| Substance abuse testing | <u>29,670</u> | <u>8%</u> | <u>20,240</u> | <u>8%</u> |
| Total clinical | <u>153,945</u> | <u>44%</u> | <u>84,932</u> | <u>33%</u> |
| Total | \$348,146 | 100% | \$254,006 | 100% |
| Total laboratory services revenue | \$219,176 | | \$151,581 | |

Volumes:

| | | |
|--------------------------|--------------|-------|
| Risk assessment services | | |
| Insurance laboratory | 3,825 | 3,862 |
| Paramedical services | 973 | 820 |
| Clinical | | |
| Healthcare services | 3,282 | 1,869 |
| Substance abuse testing | 2,350 | 1,674 |

YEAR TO DATE ANALYSIS

Revenue for the nine month period ended September 30, 2004, was \$348.1 million compared to \$254.0 million in the first nine months of 2003. The increase of \$94.1 million, or 37%, was due to increases in clinical healthcare revenue of \$59.6 million, risk assessment revenue of \$25.1 million and clinical SAT revenue of \$9.4 million. Risk assessment revenue increased to \$194.2 million from \$169.1 million in the first nine months due primarily to increases of \$13.7 million in other insurance services and \$12.9 million in paramedical services, partially offset by a decrease in insurance laboratory services of \$1.4 million. Other insurance services increased primarily due to growth in medical records retrieval, teleunderwriting services and motor vehicle reports. Paramedical services revenue increased due to an increase in the number of paramedical exams performed from new customer accounts and the acquisition of a Canadian paramedical provider. Insurance laboratory revenue decreased 2% due to a 1% decline in the total number of insurance applicants tested by the Company and a 4% decrease in the average revenue per applicant. During the first nine months of 2004, healthcare services revenue increased to \$124.3 million from \$64.7 million in 2003 due to the acquisition of Alliance Laboratory Services in January 2004 and a 21% increase in organic testing volumes. Alliance Laboratory Services accounted for \$43.7 million of the revenue increase, and increased sales to new and existing healthcare customers accounted for \$15.9 million of the revenue increase. SAT revenue increased \$9.4 million to \$29.7 million in the first nine months of 2004 from \$20.2 million in 2003 due to the acquisition of Northwest Toxicology and an 11% increase in organic testing volumes. Northwest Toxicology accounted for \$7.5 million of this increase. Total laboratory services revenue from risk assessment and clinical was \$219.2 million as compared to \$151.6 million in the first nine months of 2003.

Cost of sales increased \$65.7 million, or 38%, in the first nine months of 2004 as compared to the prior year, due primarily to the acquisitions of Alliance Laboratory Services and Northwest Toxicology, and increases in paramedical collections and physician statement fees, motor vehicle reports, payroll and lab supplies. Paramedical services increased primarily due to continued growth of the ExamOne paramedical operations. Payroll increased due to increased specimen volume in the healthcare and SAT laboratory testing segment and growth of teleunderwriting and medical records retrieval services. Risk assessment cost of sales, including all of the above mentioned factors, increased to \$140.8 million in 2004 from \$120.8 million in the first nine months of 2003. Clinical healthcare cost of sales increased to \$77.9 million as compared to \$38.1 million in the first nine months of 2003 primarily due to the addition of Alliance Laboratory Services. Clinical SAT cost of sales expenses increased to \$20.4 million as compared to \$14.4 million in the first nine months of 2003 primarily due to the addition of Northwest Toxicology.

As a result of the above factors, gross profit year to date increased \$28.4 million, or 35%, from \$80.7 million in 2003 to \$109.1 million in 2004. Risk assessment gross profit increased \$5.2 million, or 11%, to \$53.4 million in 2004. Clinical healthcare gross profit increased \$19.8 million, or 74%, to \$46.4 million in 2004 from \$26.6 million in 2003. Clinical SAT gross profit increased \$3.5 million, or 60%, to \$9.3 million in 2004 from \$5.8 million last year.

Selling, general and administrative expenses increased \$20.6 million, or 37%, in the first nine months of 2004 as compared to the prior year. This increase is primarily due to increases in payroll, bad debt and amortization expenses.

Risk assessment overhead expenditures increased to \$15.0 million in 2004 from \$13.5 million in the first nine months of 2003. Clinical healthcare overhead expenditures increased to \$26.5 million as compared to \$14.3 million in 2003 due to the acquisition of Alliance Laboratory Services and an increase in payroll expense. Clinical SAT overhead expenditures increased to \$4.2 million as compared to \$2.4 million in 2003 primarily due to the acquisition of Northwest Toxicology. Corporate overhead expenses increased to \$29.9 million from \$24.8 million in the first nine months of 2003 primarily due to higher payroll, expenses related to compliance with the Sarbanes-Oxley Act of 2002, depreciation and insurance expenses.

Operating earnings increased 30% from \$25.7 million in the first nine months of 2003 to \$33.6 million in 2004. Risk assessment services operating earnings increased 11% to \$38.4 million in 2004 as compared to \$34.7 million in 2003. Clinical healthcare services operating income increased 61% to \$19.9 million in 2004 as compared to \$12.4 million in 2003. Clinical SAT operating earnings increased 49% to \$5.1 million in the first nine months of 2004 as compared to \$3.4 million in 2003. Corporate operating expenses increased 20% to \$29.9 million compared to \$24.8 million in 2003.

Non operating expenses increased \$1.7 million primarily due to higher interest expense from increased borrowings for acquisitions. The effective income tax rate was 37% in the first nine months of 2004 as compared to 37% in 2003.

The combined effect of the above factors resulted in net earnings of \$18.8 million, or \$1.08 per diluted share in the first nine months of 2004, compared to \$15.0 million, or \$0.89 per diluted share in 2003. Convertible preferred dividends in the first nine months of 2003 were \$2.3 million and earnings available to common shareholders were \$12.6 million. The preferred stock was converted into LabOne common stock during the third and fourth quarters of 2003.

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

LabOne's working capital position increased by \$17.5 million to \$65.6 million as of September 30, 2004 from \$48.1 million as of December 31, 2003 due to an increase in cash and accounts receivable, partially offset by an increase in accounts payable and accrued payroll. Net cash provided by operations was \$37.3 million as compared to \$19.2 million in the first nine months of 2003. The increase is due to higher net income and non cash items including depreciation, deferred income taxes and the tax benefit from the exercise of stock options.

During the first nine months of 2004, the Company spent \$60.1 million on acquisitions and \$16.2 million for capital expenditures. Acquisitions included \$43.9 million for Alliance Laboratory Services and \$12.2 million for Northwest Toxicology. During the first nine months of 2003, the Company spent \$7.2 million on acquisitions and \$5.9 million for capital expenditures. The Company expects to spend approximately \$24 million for the land, building construction, furnishings, equipment and information technology systems for a new laboratory facility in Cincinnati, Ohio to be completed at the end of the second quarter of 2005. To date, the Company has spent \$3.7 million related to the new facility.

During June 2004, the Company issued \$90 million of 3.50% convertible senior debentures due June 15, 2034 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. During July 2004, the initial purchasers exercised their option to purchase an additional \$13.5 million of the debentures. The debentures may be converted, under certain circumstances, into a combination of cash and common stock of the Company at an initial rate equivalent to a conversion price of \$39.30 per share of common stock, subject to certain adjustments. Holders may convert the debentures if the common stock price exceeds 130% of the conversion price for 20 trading days in the 30 trading day period ending on the last trading day of the preceding fiscal quarter. Upon conversion, the Company will deliver cash equal to the lesser of the aggregate principal amount of debentures to be converted and the conversion obligation, and common stock in respect of the remainder, if any, of the conversion obligation. The Company may not redeem the debentures prior to June 20, 2009. Holders of the debentures may

require the Company to repurchase some or all of the debentures on June 15, 2011, 2014 and 2024 and upon certain specified corporate transactions. The Company used the net proceeds from the offering to reduce borrowings under its credit facility and for general corporate purposes.

As of September 30, 2004, borrowings under the Company's revolving credit facility were \$0.8 million. Borrowings had increased from \$47.0 million as of December 31, 2003 to \$95.7 million as of March 31, 2004 primarily to fund acquisitions. During the third quarter, the Company increased commitments under its revolving credit facility from \$150 million to \$175 million. The line of credit bears variable interest which, as of October 29, 2004, was 3.8% and requires a commitment fee of 0.5% on the unused portion of the commitment. Based on covenants, \$70.3 million of the remaining \$174.2 million was available for borrowing as of September 30, 2004.

As of September 30, 2004, the Company had \$9.0 million outstanding of industrial revenue bonds issued to finance the construction of the Company's Lenexa facility. Interest on the industrial revenue bonds is based on a taxable seven-day variable rate which, including letter of credit and remarketing fees, was approximately 2.9% as of October 29, 2004.

As of September 30, 2004, LabOne had total cash and cash equivalents of \$20.6 million as compared to \$4.7 million as of December 31, 2003. The Company expects to fund operations from a combination of cash flows from operations and borrowings under the credit facility.

ITEM 3 - Quantitative and Qualitative Disclosures about Market Risk.

As of September 30, 2004, LabOne's liability subject to variable interest rates was \$9.8 million. The associated market risk exposure is not considered to be material. A foreign currency risk exposure exists due to sales in Canada in Canadian dollars and the direct laboratory expenses associated with this revenue being incurred in US dollars. This exposure is not considered to be material.

ITEM 4 - Controls and Procedures.

The Company maintains disclosure controls and procedures that are designed for information required to be disclosed in the Company's reports filed pursuant to the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also are designed for such information to be accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met.

Management of the Company, including the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded

that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report to provide reasonable assurance that the control system's objectives would be met.

There were no changes in the Company's internal controls over financial reporting during the third quarter of fiscal 2004 that materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.

As previously reported, during the third quarter of 2004, the Company's internal auditors identified a reportable condition in the design and operation of general computer controls related to program changes and access security. The condition is not considered a material weakness. The Company believes it has addressed and remediated the issues concerning program changes. The Company has implemented certain changes in security access, and has plans for completion of remediation during the fourth quarter.

PART II. OTHER INFORMATION

ITEM 2 - Unregistered Sales of Equity Securities and Use of Proceeds

(c) In 2000, the Company's Board of Directors authorized a share repurchase program to purchase up to \$10 million of LabOne common stock. The program does not have an expiration date. During 2000, the Company repurchased 841,000 shares of common stock at an average price of \$7.07 per share for a total of \$5.9 million. The Company has not repurchased any shares of common stock since 2000. Approximately \$4.1 million remains available for future treasury stock purchases.

ITEM 6 - Exhibits

10.1 Amendment to Stock Option Agreements between the Registrant and John W. McCarty dated September 2, 2004.

10.2 Employment Agreement between the Registrant and Philip A. Spencer dated November 1, 2003.

10.3 Employment Agreement between the Registrant and L. Patrick James, M.D. dated November 19, 2003.

10.4 Form of Indemnification Agreement entered into between the Company and its directors and the following officers: W. Thomas Grant, II; John W. McCarty; Michael J. Asselta; Joseph C. Benage; Troy L. Hartman; Patrick James; Craig R. Meegan; Gregg R. Sadler; and Philip A. Spencer. Incorporated by reference to Exhibit 10.10 to the Annual Report of LabOne, Inc., a Missouri corporation, for the year ended December 31, 1999. Certain former directors and officers of the Company may also have rights under the Indemnification Agreement pertaining to actions taken while such persons were directors or officers of the Company.

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. 'SS' 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LabOne, Inc.

Date: November 9, 2004

By /s/ John W. McCarty
John W. McCarty
Executive V.P. and Chief Financial Officer